利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.022 秒)

    Modified Release Famciclovir Compositions
    2.
    发明申请
    Modified Release Famciclovir Compositions 审中-公开
    改性释放泛昔洛韦组合物

    公开(公告)号：US20100136106A1

    公开(公告)日：2010-06-03

    申请号：US11568891

    申请日：2006-06-07

    申请人： Gary Liversidge ,  Scott Jenkins ,  John G. Devane ,  Paul Stark ,  Niall Fanning ,  Gurvinder Singh Rekhi

    发明人： Gary Liversidge ,  Scott Jenkins ,  John G. Devane ,  Paul Stark ,  Niall Fanning ,  Gurvinder Singh Rekhi

    IPC分类号： A61K31/52 ,  A61K9/48 ,  A61P31/22 ,  A61P31/20 ,  A61K9/58

    CPC分类号： A61K9/5078 ,  A61K9/5026 ,  A61K9/5084

    摘要： The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers famciclovir in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition, and to a method for the treatment or suppression of viral infections.

    摘要翻译： 本发明涉及一种多微粒改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送泛昔洛韦。 多微粒改性释放组合物包含第一组分和至少一个后续组分，第一组分包含含有颗粒的第一组活性成分和至少一种随后的组分，其包含第二组含有颗粒的活性成分。 本发明还涉及含有这种多微粒改性释放组合物的固体口服剂型，以及用于治疗或抑制病毒感染的方法。

    Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
    6.
    发明申请
    Pharmaceutical formulations for carrier-mediated transport statins and uses thereof 有权
    用于载体介导的运输他汀类药物的制剂及其用途

    公开(公告)号：US20050119331A1

    公开(公告)日：2005-06-02

    申请号：US10967167

    申请日：2004-10-19

    申请人： Jackie Butler ,  John Devane ,  Paul Stark

    发明人： Jackie Butler ,  John Devane ,  Paul Stark

    IPC分类号： A61K9/20 ,  A61K9/28 ,  A61K31/40 ,  A61K31/505 ,  A61K31/401 ,  A61K31/225 ,  A61K31/366

    CPC分类号： A61K31/505 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/284 ,  A61K9/2846 ,  A61K31/40 ,  C07D207/34

    摘要： The present invention relates to formulations comprising therapeutically effective amounts of at least one acid-stable, carrier-mediated transport statin, at least one poorly water-soluble, carrier-mediated transport statin, or at least one large molecular weight, carrier-mediated transport statin, such as atorvastatin and rosuvastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to exhibit a controlled-release of a therapeutic amount of the statin in the small intestine, thereby limiting systemic exposure of the statin and maximizing liver-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.

    摘要翻译： 本发明涉及包含治疗有效量的至少一种酸稳定的载体介导的转运他汀类药物，至少一种难溶于水的载体介导的转运他汀类药物或至少一种大分子量的载体介导的转运体 他汀类药物，如阿托伐他汀和罗苏伐他汀，或其药学上可接受的盐及其使用方法。 本发明的制剂和方法设计用于在小肠中显示治疗量的他汀类药物的受控释放，从而限制他汀类药物的全身暴露并使药物的肝脏特异性吸收最大化。 本发明的制剂和方法特别可用于治疗和/或预防通过降低体内脂质和/或胆固醇水平而受益的病症。

    Nanoparticulate and controlled release compositions comprising nilvadipine
    8.
    发明申请
    Nanoparticulate and controlled release compositions comprising nilvadipine 审中-公开
    包含尼伐地平的纳米颗粒和控释组合物

    公开(公告)号：US20100247636A1

    公开(公告)日：2010-09-30

    申请号：US11479013

    申请日：2006-06-30

    申请人： John G. Devane ,  Paul Stark ,  Niall M.M. Fanning ,  Gurvinder Singh Rekhi ,  Scott A. Jenkins ,  Gary Liversidge

    发明人： John G. Devane ,  Paul Stark ,  Niall M.M. Fanning ,  Gurvinder Singh Rekhi ,  Scott A. Jenkins ,  Gary Liversidge

    IPC分类号： A61K9/48 ,  A61K31/4422 ,  A61K9/14 ,  A61K9/50 ,  A61K9/26 ,  A61K9/22 ,  A61P9/12 ,  A61P9/00

    CPC分类号： A61K9/5026 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/192 ,  A61K31/485

    摘要： The present invention provides a composition comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, useful in the treatment and prevention of hypertension or related cardiovascular disorders. In one embodiment, the composition comprises nanoparticulate particles comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of hypertension or related cardiovascular disorders.

    摘要翻译： 本发明提供一种组合物，其包含可用于治疗和预防高血压或相关心血管疾病的尼伐地平或其盐，衍生物，前药或多晶型物。 在一个实施方案中，组合物包含包含尼伐地平或其盐，衍生物，前药或多晶型物和至少一种表面稳定剂的纳米颗粒颗粒。 纳米颗粒具有小于约2000nm的有效平均粒度。 在另一个实施方案中，组合物包含改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送尼伐地平或其盐，衍生物，前药或多晶型物。 本发明还涉及含有这种组合物的剂型，以及治疗和预防高血压或相关心血管疾病的方法。

    Modified Release Ticlopidine Compositions
    9.
    发明申请
    Modified Release Ticlopidine Compositions 审中-公开
    改良释放噻氯匹定组合物

    公开(公告)号：US20090297597A1

    公开(公告)日：2009-12-03

    申请号：US11569481

    申请日：2006-06-09

    申请人： Gary Liversidge ,  Scott Jenkins ,  Paul Stark ,  Niall M.N. Fanning ,  Gurvinder Singh Rekhi ,  John G. Devane

    发明人： Gary Liversidge ,  Scott Jenkins ,  Paul Stark ,  Niall M.N. Fanning ,  Gurvinder Singh Rekhi ,  John G. Devane

    IPC分类号： A61K9/48 ,  A61K9/00 ,  A61K9/14 ,  A61K31/4365 ,  A61K9/58 ,  A61K9/60 ,  A61P43/00

    CPC分类号： A61K9/5026 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/192 ,  A61K31/485

    摘要： The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers ticlopidine in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles. The invention also relates to a solid oral dosage form containing such multiparticulate modified release composition, and to methods for inhibiting platelet aggregation, inhibiting blood clotting, and reducing risk of stroke in a patient.

    摘要翻译： 本发明涉及一种多微粒改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送噻氯匹定。 多微粒改性释放组合物包含第一组分和至少一个后续组分，第一组分包含含有颗粒的第一组活性成分和至少一种随后的组分，其包含第二组含有颗粒的活性成分。 本发明还涉及含有这种多微粒释放组合物的固体口服剂型，以及用于抑制血小板聚集，抑制血液凝固和降低患者中风风险的方法。